FILING ANALYSIS · THURSDAY, NOVEMBER 5
IOVANCE BIOTHERAPEUTICS, INC. IOVA — 8-K: Results of Operations and Financial Condition
positive
Iovance Biotherapeutics reported record third-quarter revenue of ~$122 million, an 80% increase year-over-year, and a gross margin of ~60%, driven by continued demand for U.S. Amtagvi, with the company remaining on track to achieve its full-year 2026 total revenue guidance of $410 to $420 million.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →